Aspirin Use in Hemodialysis Patients

Introduction to Aspirin and Hemodialysis

The American Journal of Kidney Diseases recommends against using aspirin for preventing dialysis access thrombosis in hemodialysis patients, due to a randomized controlled trial of aspirin plus clopidogrel versus placebo being terminated early because of gastrointestinal bleeding without demonstrating efficacy for preventing AV graft thrombosis 1, 2, 3, 4

A randomized controlled trial testing aspirin plus clopidogrel versus placebo to prevent AV graft thrombosis was stopped prematurely because of excessive GI bleeding complications, representing the highest-quality evidence directly addressing the use of antiplatelet therapy for dialysis access protection 1, 2, 3, 4
No randomized controlled trials in dialysis patients have established the safety and efficacy of aspirin for preventing vascular access thrombosis 1, 2, 3, 4

It is essential to distinguish between aspirin for cardiovascular disease prevention and aspirin for dialysis access thrombosis prevention, where the evidence shows harm without proven benefit 1, 2, 3, 4

The American College of Physicians and other guideline societies advise against prescribing aspirin specifically to prevent dialysis catheter or fistula clotting, as this indication lacks supporting evidence and exposes patients to bleeding risk, particularly GI hemorrhage 1, 2, 3, 4